ARMEN GARO H purchased $710 of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,220 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.32 on 2026-08-11.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market purchase details (2,220 shares at $0.3200) by the company’s Exec Chair and Principal Officer, filed on 2026-08-12.
Market read
Traders may note the insider buy, but there is no accompanying fundamental catalyst in the text.
What to watch
The article does not state whether the insider has a broader pattern of buying/selling, nor does it provide context on total holdings changes beyond the post-transaction share count.
Background
The article is a SEC Form 4 insider transaction disclosure for Protagenic Therapeutics, Inc.
Ticker impact
Protagenic Therapeutics disclosed an insider open-market purchase by Exec Chair Armen Garo H of 2,220 shares at $0.3200 on 2026-08-11.
Low likelihood of a sustained price move based solely on this filing.
The filing is a disclosed insider transaction, but it is not tied to new company guidance, contracts, clinical results, or financing, and the disclosed value ($710) is modest.
Market effects
Minimal, as the disclosure does not include sector-wide regulatory, clinical, or financing developments.
None indicated.
None indicated.
Counterpoint
Insider buys can be informative, but without a 10b5-1 plan and with a small dollar amount, the signal may be noise rather than a conviction indicator.
Key entities
- issuerProtagenic Therapeutics, Inc.
Company whose insider transaction was disclosed on SEC Form 4.
- insiderARMEN GARO H
Exec Chair and Principal Officer who purchased shares directly.